Cover Image

Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study

Organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 are involved in the disposition of a variety of commonly prescribed drugs. The evaluation of OATP1B1/1B3 inhibition potential by investigational drugs is of interest during clinical drug development due to various adverse events associate...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hari V. Kalluri (Author), Ryota Kikuchi (Author), Sheryl Coppola (Author), Jeffrey Schmidt (Author), Mohamed‐Eslam F. Mohamed (Author), Daniel A.J. Bow (Author), Ahmed H. Salem (Author)
Format:	Book
Published:	Wiley, 2021-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Relationship of hemoglobin level and plasma coproporphyrin‐I concentrations as an endogenous probe for phenotyping OATP1B
by: Yosuke Suzuki, et al.
Published: (2021)

The influence of OATP2B1 and atorvastatin on coproporphyrin isomers in rats
by: Jonny Kinzi, et al.
Published: (2023)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
by: Cotter TG, et al.
Published: (2019)

Characterizing complex and competing drug-drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine
by: Matthew P. Kosloski, et al.
Published: (2023)

A possible case of maculopapular eruption associated with glecaprevir/pibrentasvir treatment for chronic hepatitis C virus infection
by: Hiroka Tomiyasu, et al.
Published: (2021)

Substantially Increased Plasma Coproporphyrin‐I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population
by: Yosuke Suzuki, et al.
Published: (2021)

A comparison of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of hepatitis C infection among people who inject drugs
by: Shana Yi, et al.
Published: (2024)

Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study
by: Bahtiyar Yilmaz, et al.
Published: (2021)

P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1-6 patients without cirrhosis
by: Massimo Puoti, et al.
Published: (2017)

P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure
by: Fred Poordad, et al.
Published: (2017)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug-drug interactions from coproporphyrin I to probe drugs
by: Tatsuki Mochizuki, et al.
Published: (2022)

Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B‐mediated rifampicin interaction studies
by: Takashi Yoshikado, et al.
Published: (2022)

Sofosbuvir más glecaprevir/pibrentasvir como terapia de rescate postrasplante hepático en pacientes con exposición previa a inhibidores de NS5A. Serie de casos
by: Ignacio García-Juárez, et al.
Published: (2023)

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B
by: Shinji Nakayama, et al.
Published: (2023)

Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions
by: Ruhul Kayesh, et al.
Published: (2023)

Assessing <i>Trans</i>-Inhibition of OATP1B1 and OATP1B3 by Calcineurin and/or PPIase Inhibitors and Global Identification of OATP1B1/3-Associated Proteins
by: John T. Powell, et al.
Published: (2023)

Transcriptional Regulation of Liver-Type OATP1B3 (Lt-OATP1B3) and Cancer-Type OATP1B3 (Ct-OATP1B3) Studied in Hepatocyte-Derived and Colon Cancer-Derived Cell Lines
by: Bastian Haberkorn, et al.
Published: (2023)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
by: Dominique A. Garrison, et al.
Published: (2020)

Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells
by: Marie Brännström, et al.
Published: (2015)

Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates
by: Samantha Medwid, et al.
Published: (2021)

Ginsenoside Rb1 and Rd Remarkably Inhibited the Hepatic Uptake of Ophiopogonin D in Shenmai Injection Mediated by OATPs/oatps
by: Xiaopei Liu, et al.
Published: (2018)

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
by: Uta Schilling, et al.
Published: (2020)

Endogenous glucocorticoids may serve as biomarkers for migraine chronification
by: Yohannes W. Woldeamanuel, et al.
Published: (2020)

Various effects of repeated rifampin dosing on coproporphyrin levels in humans
by: Jonny Kinzi, et al.
Published: (2023)

PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability
by: Hiroyuki Takita, et al.
Published: (2021)

¿Conocemos todas las interacciones farmacológicas?: el transportador OATP1B1
by: Martínez Celdran LM, et al.
Published: (2018)

Probable interacción entre Olmesartán y Rosuvastatina por inhibición de OATP1B1
by: Rodríguez Arcas MJ
Published: (2018)

Increased coproporphyrin serum levels in healthy volunteers treated with the cholesterol uptake inhibitor ezetimibe
by: Jonny Kinzi, et al.
Published: (2024)

Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3
by: Robert Elsby, et al.
Published: (2023)

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
by: Eric D. Eisenmann, et al.
Published: (2022)

Berberine Promotes OATP1B1 Expression and Rosuvastatin Uptake by Inducing Nuclear Translocation of FXR and LXRα
by: Mingyi Liu, et al.
Published: (2020)

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters
by: Susan E. Shoaf, et al.
Published: (2021)

Relationship of plasma 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid concentration with OATP1B activity in patients with chronic kidney disease
by: Hiroyuki Ono, et al.
Published: (2024)

Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1)
by: Ágnes Dombi, et al.
Published: (2024)

Variability in In Vitro OATP1B1/1B3 Inhibition Data: Impact of Incubation Conditions on Variability and Subsequent Drug Interaction Predictions
by: Savannah J. McFeely, et al.
Published: (2020)

OATP1A2 mediates Aβ1-42 transport and may be a novel target for the treatment of Alzheimer's disease
by: Jinhua Wen, et al.
Published: (2024)

Validation of Mct8/Oatp1c1 dKO mice as a model organism for the Allan-Herndon-Dudley Syndrome
by: Gandhari Maity-Kumar, et al.
Published: (2022)

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities
by: Yang Li, et al.
Published: (2022)

Determination of single-molecule transport activity of OATP2B1 by measuring the number of transporter molecules using electrophysiological approach
by: Kodai Yajima, et al.
Published: (2023)

Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms
by: Seung-Hyun Jeong, et al.
Published: (2022)